TY - JOUR
T1 - Aspirin and ovarian cancer
T2 - An italian case-control study
AU - Tavani, A.
AU - Gallus, S.
AU - La Vecchia, C.
AU - Conti, E.
AU - Montella, M.
AU - Franceschi, S.
PY - 2000
Y1 - 2000
N2 - Background: A role for inflammation, and consequently of non-steroideal anti-inflammatory drugs, in ovarian carcinogenesis has been proposed, but epidemiological evidence is scanty. Patients and methods: Data were derived from a hospital-based case-control study conducted in Italy between 1992 and 1999. Cases were 749 women, aged 18-80 years (median age 56 years), with incident, histologically confirmed ovarian cancer. Controls were 898 non-hysterectomized women, aged 17-80 years (median age 58 years), admitted to hospital for acute conditions, unrelated to risk factors for ovarian cancer. Results: The multivariate odds ratio (OR) was 0.93 (95% confidence interval (95% CI): 0.53-1.62) for regular aspirin use for more than six months, 1.38 (95% CI: 0.57-3.36) for current use and 0.72 (95% CI: 0.35-1.47) for former use. The OR was not significantly different from unity for duration of use, age at starting use, indication (analgesia or cardiovascular prevention), and in women aged
AB - Background: A role for inflammation, and consequently of non-steroideal anti-inflammatory drugs, in ovarian carcinogenesis has been proposed, but epidemiological evidence is scanty. Patients and methods: Data were derived from a hospital-based case-control study conducted in Italy between 1992 and 1999. Cases were 749 women, aged 18-80 years (median age 56 years), with incident, histologically confirmed ovarian cancer. Controls were 898 non-hysterectomized women, aged 17-80 years (median age 58 years), admitted to hospital for acute conditions, unrelated to risk factors for ovarian cancer. Results: The multivariate odds ratio (OR) was 0.93 (95% confidence interval (95% CI): 0.53-1.62) for regular aspirin use for more than six months, 1.38 (95% CI: 0.57-3.36) for current use and 0.72 (95% CI: 0.35-1.47) for former use. The OR was not significantly different from unity for duration of use, age at starting use, indication (analgesia or cardiovascular prevention), and in women aged
KW - Aspirin
KW - Inflammation
KW - NSAID
KW - Ovarian neoplasms
KW - Pharmacoepidemiology
KW - Risk factors
KW - Salicylates
UR - http://www.scopus.com/inward/record.url?scp=0033784786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033784786&partnerID=8YFLogxK
U2 - 10.1023/A:1008373616424
DO - 10.1023/A:1008373616424
M3 - Article
C2 - 11061614
AN - SCOPUS:0033784786
SN - 0923-7534
VL - 11
SP - 1171
EP - 1173
JO - Annals of Oncology
JF - Annals of Oncology
IS - 9
ER -